Bind Therapeutics (BIND) is a bio-pharmaceutical company developing therapeutic targeted nano-particles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010. BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nano-particles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).

BIND was acquired by Pfizer in 2016.